Indigenous and improved fungally fermented cbd, cbg and related cannabinoid oral dosage forms

ABSTRACT

The present invention is a novel and enhanced co-fermentation product of hemp and cannabis, in which 1 part by weight shredded or divided hemp stems, leaves and flowers are admixed into a slurry with at least one part by weight up to two parts by weight water and the slurry is sterilized prior to inoculation with solid or liquid mycelium culture. After inoculation, fermentation takes place at 66-70 degrees F. for 14-28 days, followed by drying of the fermented admixture at 110-165 degrees F. for 24-48 hours, prior to co-minuting or powdering the dried end product for incorporation in oral dosage forms such as pressed tablets, manufactured capsules or powder or as an ingredient in functional foods. By following these method steps including the initial creation of aqueous hemp slurry with the prescribed ratio ranges of water, both hemp and mushroom component conversions occur to an unexpected degree.

CROSS-REFERENCE TO RELATED APPLICATIONS

This patent application claims priority to U.S. Provisional PatentApplication 62/912,930 filed 9 Oct. 2019, which is incorporated hereinby reference, and likewise claims priority to U.S. patent applicationSer. No. 16/871,535 filed 11 May 2020, which itself claims priority toU.S. 62/912,930 filed 9 Oct. 2019 and which (Ser. No. 16/871,535) isalso incorporated herein by reference.

FIELD OF THE INVENTION

The invention pertains to improved CBD and CBG (and relatedcannabinoids) delivery methods and dosage forms, namely, containingfermented hemp using a medicinal fungi culture.

BACKGROUND OF THE INVENTION

Cannabis indica, Cannabis sativa and Cannabis ruderalis are wellestablished both as herbs and pharmaceuticals throughout history. Moreelusively but still historically, fungiculture is also a wellestablished technology in the culinary and pharmaceutical arts. Bothcannabis and mushrooms enjoy a deep mystique in addition to their longhistories, and both are also understood to embody—in the wrong hands—anelement of danger as well. A recognized leader (if not “Father”) ofmodern Cannabis chemistry is Raphael Mechoulam, who spoke in April of2019 to the ICBC International Cannabis Business Conference. Inrecounting his particular interest and history in studying cannabis, hebegan his keynote address remembering that “In ancient Syria they usedcannabis for essentially all the things that people use cannabis fortoday” and that “Cannabis was then used over the next couple of thousandyears.” With Cannabis indica, Cannabis sativa and Cannabis ruderalishaving thus had a long tenure as known active agents, The HistoryChannel recently devoted an entire special issue magazine to the storyof Cannabis throughout the world, indicating (without limitation) thatQueen Victoria's physician probably prescribed versions of Cannabismedicaments for pain management, and so forth. Mechoulam corroboratedthis connection of Cannabis to royalty in his keynote, explaining that“Dr Russell Reynolds, who was the physician of Queen Victoria inEngland, used to import [cannabis] from India (European cannabis was notgood enough for him) because she suffered from migraines.”Whereas thereare no specific historic references to administration of Cannabis to theQueen at that time, Mechoulam points out that “it was obvious who it wasfor because she was the only patient that he had.” With a fast forwardto the 2018 “Farm Bill” (Agricultural Improvements Act of 2018, 115thCongress, 2017-2018) the United States law now acknowledges thatindustrial hemp, a cannabis plant with less than 0.3%tetrahydrocannabinol (THC), is not “marijuana” for the purpose of theControlled Substances Act. This means that hemp-derived cannabidiol(CBD) and related cannabinoids such as cannabigerol (CBG) andcannabichromene (CBC) can now ostensibly be produced and sold asconsumable agricultural products in the United States, whereas prior tothe 2018 Farm Bill hemp could be grown and used in the U.S. only forresearch purposes under individual states' pilot programs and in certaincategories such as clothing, industrial materials and products made fromthe plant's stalks or seeds. In other words, 2018 was a watershed yearfor health care providers, consumer packaged goods companies and thepharmaceutical industry, creating for the first time a legal (ornascently legal) domestic source of cannabinoids (initially focused onCBD)—from U.S.-grown hemp.

Thus, in the right hands, both cannabis and mushrooms represent virtualpharmaceutical factories of important wellness and nutraceuticalnutrients and compounds. Now that more-retail-cash-registers-than-notoffer various CBD or other cannabinoid products for sale—sometimes manyedible offerings such as individually wrapped chocolates containingcannabinoids along with topicals, oils and capsules—an interestingquestion remains—what magic might Cannabis and mushrooms make together?

As with any newly popular ingredient, there are opportunities for highquality products as well as those of lesser value and benefit. There arecurrently reliable, responsible hemp growers and manufacturers and,presumably, also formulators and peddlers reminiscent of the “snake oilsalesmen” of the American 1800s. Chinese snake oil was a legitimateanti-inflammatory substance for decades if not centuries, prior to fakeiterations that appeared later in the U.S. The original Chinese snakeoil was made from the oil of the Chinese water snake, which was rich inthe omega-3-fatty acids that are known to reduce inflammation. This“snake oil” in its original form was indeed effective as a topicalmedicament to treat arthritis and bursitis and, eventually, the putativeproduct made its way to the United States—if not the omega-3-rich watersnake itself, or its curative extract. The point here is that withhemp-derived cannabinoids, as with anything else, responsible sourcing,processing and quality control in manufacturing are the bedrock of anysuperior pharmaceutically active agent. The pressures of manufacturingin light of a population clamoring for cannabinoids are particularlyintense, in world in which side-effect- or addiction-minimized painmanagement is still an elusive if (not scandal-laden) goal.

It is interesting that, as a general practice regardingnaturally-occurring active agents—and particularly those of herbalsources—there seems to be a knee-jerk compulsion to extract andsynthesize the active agent or chemical compound from its botanical(herb or spice) source. Extracting and synthesizing digitalis fromfoxglove, a natural herb, is of course a prime example in pharmaceuticalhistory. In theory there is nothing wrong with extractionprocesses—although in practice there can indeed be negative implicationsto extraction, in particular as to the molecule(s) to be extracted.Extraction agents such as petroleum or coal-tar derived solvents cancreate residues or even alter the chemical composition of thesought-after molecule. Worse, beneficial co-factors present in thenatural product, in this case an herb, can be separated from the activeagent so as to lose the synergy of administration of the whole herb withits known and yet-to-be discovered compounds. Even today, when Cannabisindica, Cannabis sativa and Cannabis ruderalis are on the brink ofbecoming “health food” [so to speak] instead of “Just Say No!” fodder,the temptation seems to be ubiquitous to extract, isolate and evensynthesize key constituents within them, in order to obtain their activecompound(s) for further commercialization. The question which thepresent inventor asked, therefore, was—whether traditional extraction orisolation is the only processing method that can deliver the truebenefits of hemp and its constituent cannabinoids, when the use of hempand mushrooms (fungi) are contemplated together? And, if extraction orisolation is not the best approach, what additional beneficialconversions are possible to enhance the power and constituency of hempand fungi for functional foods and dietary supplementation?

SUMMARY OF THE INVENTION

The present invention is a novel and enhanced co-fermentation product ofhemp and cannabis, in which one part by weight shredded or divided hempaerial parts, primarily leaves and flowers, are admixed into a slurrywith at least one up to two parts by weight water, and the slurry thuscreated is sterilized prior to inoculation with solid mycelium culture.After inoculation, fermentation takes place at 66-70 degrees F. for14-28 days, followed by drying of the fermented admixture at a constanttemperature of 115-165 degrees F. for 24-48 hours, prior to co-minutingor powdering the dried fermentation product for incorporation in oraldosage forms such as pressed tablets, manufacture capsules, nutritionalpowders or in functional foods and beverages. Hemp and mushroom culturesco-fermented in this way creates unique composite nutraceuticalscontaining properties unattainable in either hemp or mushrooms alone.The inventive method is different from traditional mushroom culture inmany ways, including but not limited to the typical solid mediumfungiculture of the prior art, which largely or completely separate themushrooms from their growth media. The present method steps, moreover,contribute to new and unexpectedly improved results as to constituentdiversity in the fermentation product. By following the inventive methodsteps including the initial creation of the at least 1:1 aqueous: hempslurry up to 2:1 water: hemp, both hemp and mushroom componentconversions occur to an unexpected degree.

DETAILED DESCRIPTION OF THE INVENTION

The present supplement, pharmaceutical and nutraceutical preparation andmethod for delivering active ingredients, center on a powdered form of afermented, native or activated unextracted hemp biomass containingcannabinoids including but not limited to cannabidiol (CBD) andcannabigerol (CBG), dietary fiber of a particular ratio, vitamins,minerals, flavonoids, terpenes, fatty acids and amino acids. The powdercan be optionally blended with other botanical ingredients andcompressed into a tablet form, encapsulated or manufactured into anutritional powder for administration to or consumption by an animal orhuman in need of a reliably sourced cannabinoid oral dosage form.Fermentation is conducted with any complex fungi (nutritional orculinary fungi or mushroom mycelial culture) suitable for consumption ororal administration, including but not limited to Ganoderma lucidum,Ganoderma japonicum, Ganoderma applanatum, Ganoderma tsugae, Lentinulaedodes, Grifola frondosus, Tremella fuciformia, Tremella mesenterica,Cordyceps sinensis, Cordyceps militaris, Hericium erinaceus, Polyporousumbellatus, Scizophylum commune, Fomes fomentaris, Inonotuus obliquus,Lepiota procera, Auricularia auricula, Tuber melanosporum, Tricholomamatsutake, Hericium coralloides, Trametes versicolor, Phellinus linteus,Poria cocos, Antrodia camphorata, Flammulina velutipes, Pleurotusostreatus, Pleurotus energyii, or Agaricus blazeii. The co-fermentedcultured material is carefully dried and comminuted into a powder priorto inclusion in a dosage form, such as a pressed tablet or manufacturedcapsule. Such a dosage form containing the inventive powders retainsbioactive fungal compounds from the fermentation, alongside cannabinoidand botanical constituents. While the present fermented native oractivated hemp biomass is well suited for use alone, it may be admixedwith other ingredients, whether active agents or excipients, fillers orcomestible ingredients comprising dietary supplements or functional foodingredients. Hemp for the purpose of this patent application is hempwhich meets the standards of the 2018 Farm Bill, that is, is a nativeCannabis (various species and varieties) which contains no more than0.3% tetrahydro cannabinol (THC) on a dry weight basis. Activated hempis hemp that has been heated or treated, with more discussion regardingactivation and its consequences' appearing later in this specification.Native hemp is raw, that is, unheated and untreated, hemp. Native oractivated hemp which remain unextracted, for the purposes of the presentfungal fermentation and further steps, contain interesting naturallyoccurring co-factors, known and currently unknown, including withoutlimitation other cannabinoids, dietary fiber, fatty acids, amino acids,and flavonoids. These known and unknown co-factors inevitably enhanceany or all of delivery, bioavailability and efficacy of theCBD/cannabinoid(s) in vivo.

This invention takes the native or activated hemp starting material andsubjects it to sterilization followed by fungal fermentationspecifically with mushroom or fungi mycelia, to convert and enhance theconstituent molecules and compounds in the hemp to an increasinglydiverse and prized spectrum of nutrients and active agents—all whilekeeping the hemp (or cannabis) in its unextracted state. A key part ofthe present invention therefore inheres in the synergy achieved by usingunextracted hemp (or cannabis) as the starting material for a mushroomculture fermentation, and deploying the fermentation product as afurther constituent, usually powdered, in a tablet or capsule (orequivalent) ingredient as a CBD/CBG/cannabinoid oral dosage form or inother comestible dietary supplements or functional foods. Careful dryingtechniques are used after fermentation.

Another key component to the invention is in the engineering of thecannabinoid delivery system, with a beneficial soluble dietary fiber(SDF)/insoluble dietary fiber (IDF) ratio, in the unextracted native oractivated hemp itself, of 1:30 SDF/IDF, allowing for effectiveformulation and delivery of key constituents.

Finally, the invention inheres in part in the unique method for makingthe fermented hemp, as follows. First a slurry is prepared with theunextracted native or activated hemp (and optionally another botanical)with the hemp-to-water ratio being at least one part water by weight andone part hemp by weight, up to two parts water by weight to one parthemp by weight. If another botanical is present, it is not countedtoward the hemp to water ratio. The slurry preferably contains hempparticles smaller in major dimension than 1 cm, which can be prepared bymechanical shearing techniques known in the art. The slurry thus formedis sterilized by heating it at 200-250 degrees F. and optionallyincreased pressure for 2-4 hours—mushroom culture always takes place insterilized media and the sterilization step does not form a part of thepresent inventive method. However, the use of 2 parts water to one parthemp does form part of the inventive method, together with the importantpost-sterilization steps of fermenting at 66-70 degrees F. for 14-28days, followed by drying of the fermented admixture at 110-165 degreesF. for 24-48 hours, followed by co-minuting or powdering the dried endproduct for incorporation in oral dosage forms such as pressed tablets,or in functional foods. By following the above described method stepsincluding the initial creation of the 1:1 to 2:1 aqueous: hemp slurry,both hemp and mushroom component conversions occur to an unexpecteddegree discussed further, below.

As with popular or over-the-counter dosage forms, particularly foractive agents known to control pain, dosing is tantamount to safe andeffective treatment. When it comes to CBD or CBG, general dosingguidelines suggest that a recommended initial dose is somewhere in therange of 2.5-5 mg, once or twice a day, for an averaged sized humanpatient, with possible safe and effective dosing of up to 20 mg taken asoften as three times per day. Veterinary dosing is generally pro rata bybody mass/weight at similar levels. As the cannabinoid industry matures,inevitably further dosing guidelines will become available—but as withall active agents a serious challenge is to prevent inadvertent (orintentional) overdose. One benefit of the present formulations inheresin the retained diluent function of the whole native hemp or activatedhemp (or native cannabis or activated cannabis), compared to otherdosage forms that contain extracts, which retained diluent in turnassures relatively lower dosing in the inventive material per se. Inaddition to the lower cannabinoid (i.e. CBD, CBG) concentration, alongwith synergistic co-factors which provides a more balanced, “whole food”effect with less chance of deleterious side effects, the ability of thepresent fungal fermentation to increase the profile of desirableconstituents only enhances the value of the present method and product.In addition, the ratio of soluble dietary fiber (SDF) to insolubledietary fiber (IDF) will remain similar but not exactly the same as inthe starting hemp. This SDF/IDF ratio is slightly higher than 1:30, thatis, for every slightly-more-than 1 part of soluble dietary fiber in thecannabis (native or activated), there is also 30 parts insoluble dietaryfiber, and the fungal fermentation process itself is responsible forincreasing the digestibility of the dietary fiber fraction of thecannabis in a beneficial way.

If native or activated hemp has, for example, a starting content of 10%CBD, one gram of the hemp starting material will contain about 100 mgCBD. When one cultures one gram hemp with fungus according to thepresent method, approximately ⅓ of the fermentation product is mushroommass and ⅔ is cannabis or cannabis plus bontanical(s), reducing the CBD(in this case) content to about 67 mg CBD. However, much more goes onduring fungal fermentation than merely a dilution of the cannabis with aco-created mushroom mycelial biomass. Importantly, fungal fermentationof cannabis uniquely causes conversion of indigestible fiber in thecannabis into bioactive pharmaceutical or nutritional compounds. This isa fiber conversion such as only a mushroom culture can do!—whichconversion in turn has three ramifications. First, when cannabis isco-fermented with fungi, the conversion of some of the indigestibledietary fiber inherently increases the bioavailability of the botanical,in this case hemp. Second, the mushroom fermentation does not simplyconvert insoluble dietary fiber in the cannabis to soluble dietaryfiber, but creates a wide panoply of fermentation products of to createa broad spectrum of nutrients and bioactive compounds that were notpresent in the cannabis to start with. Also, mushroomculture—particularly according to the present specific method—activatesor potentiates biologically active compounds in the cannabis, and notjust the cannabinoids. Again, a wide variety of nutrients and beneficialcompounds in the cannabis are made more bioavailable due toco-fermentation with a mushroom mycelial culture, by a number ofmechanisms including but not limited to solubilization, digestion,encapsulation, and derivatization. The present invention does not claimto be the first to harness the power of mushroom culture forbioconversion—but the present technology does represent and new andsurprisingly improved method of enhancing this biodiversity with theparticular method steps which enhance all these biological processes inways never before achieved. All this means that, by co-fermentingcannabis with mushroom mycelial culture, a greater panel of constituentcompounds and compositions will result compared to the compounds andcompositions present in the original cannabis, due to the complex andfacilitated conversions that occur resulting from the present methodsteps. Finally, the fungal growth of the present invention inherentlyproduces antibacterial, anti-yeast and anti-viral compounds, and by theuse of the present method steps including the drying method, thesedesirable antimicrobial compounds are retained in the final end productand are then combined with an wide-spectrum of active agents disclosedherein.

It almost goes without saying that organically sourced hemp (cannabis)is the best choice for the hemp starting material according to thepresent invention. By using organic hemp or cannabis, the presence ofpesticides or other solvent residues or undesirable adulterants in thehemp is reduced to a beneficial minimum. Not only is the reduction ofthese extraneous contaminants good in and of itself, but the absence ofunwanted residues maximizes the original confluence of the indigenouscannabinoids such as CBD with its synergistic co-factors, known (seelist above) or unknown. Of course even though the present invention islimited, as to commercialization, at this writing to hemp under the 2018Farm Bill, during the life of this patent as the laws may change, theinvention will be understood to embrace all cannabis as can be legallyfermented according to this invention.

Fermented hemp using fungal culture according to the present inventionis typically dried as described above and co-minuted prior totabletting, encapsulating or powdering or other end use. Dehydration toa moisture content of below 15%, preferably below 10% and morepreferably to 5-6% is important in the creation of the present oraldosage forms, but only at the specified heat. The co-minution may be butneed not be to a (small) particle size generally within the range ofpowders. Generally speaking, fermented hemp particles of at least 100microns in diameter, up to irregularly shaped particles of up to about 5mm in their longest dimension, are best for tabletting or encapsulatingaccording to the present invention. Surprisingly, hemp/mushroomparticles of this size are beneficially self tabletting without addedingredients and with a minimum of compression energy, that is, notenough pressure to generate significant heat. Avoidance of excessiveprocessing also prevents the generation of unwanted heat that candenature cannabinoids (CBD, CBG) or additional cofactors in the hempsuch as terpenes. Having said that, however, the administration ofhemp/mushroom co-fermentation product as a powder (that is, intraditional powder particle size distributions smaller than 100 microns)and as predominantly the only oral dosage form constituent as describedabove—is still within the scope of the present invention.

The primary disclosure of this patent application is directed to dosageforms in which—with few exceptions such as added inert excipients,probiotics, botanicals, vitamins and minerals or adjusted or retainedmoisture—fermented hemp using a fungal culture is the main ingredient inan oral dosage form. Having said that, the subject fermented hemp (orcannabis) has all sorts of secondary benefits as additives to otherdietary supplements, nutritional dosage forms and functionalfoods—virtually without limitation.

As disclosed above, hemp (after fungal fermentation) contains totaldietary fiber (TDF) having a ratio of slightly more than 1 part SDF to30 parts IDF (meaning a resulting ratio of 1 part SDF to 25-29 partsIDF). As compared to much higher SDF-containing botanicals, such as forexample oat or wheat bran, a ratio of 1:30 SDF/IDF—and even the reducedSDF/IDF ratio of 1:25-29—is a notably low SDF level than other “highfiber” comestibles. For the purposes of the present invention, this highinclusion of IDF is extremely beneficial to delivery of CBD and othercannabinoids from an oral dosage form—even though the fungalco-fermentation increases the native cannabis SDF component slightly.The benefits are explained as follows. SDF, upon oral administration,tends to create a sol/gel in the gastrointestinal tract, which in turnstends to retain in solution, i.e. binding or suspension, other moleculesin its vicinity such as, in this case, cannabinoids. In other contextsbesides cannabinoid administration, SDF is a highly desirable compound,that can even be partially digested by bacteria in the gut, but in thecontext of a cannabinoid delivery system SDF actually creates anunwanted binding system and subsequent elimination of cannabinoids,rather than a true delivery (release) system from the gut into the bloodstream. By contrast, the high IDF inclusion assures the desirablerelease of the cannabinoid active agent promptly if not instantly in thestomach or upper gastrointestinal tract. The present co-fermentationproduct of cannabis and mushrooms, prepared by the present method steps,gives a “best of both worlds” phenomenon, in that a minor fraction ofthe IDF is metabolized by the mushroom culture creating new andbeneficial compounds (fungal metabolites) to enhance, by rebalancing,the SDF fraction slightly, and yet the desirable high IDF ratio ispredominantly maintained while at the same time the spectrum ofconstituents metabolized by the mushrooms from the IDF is broadened inthe end fermentation product. As set forth above, the inventor believesthat this slight alteration in SDF/IDF ratio amounts, in reality, to anadjusted SDF/IDF ratio of 1:25-29.

Important cannabinoids in hemp are not limited to cannabidiol (CBD).Known significant cannabinoids other than THC include, withoutlimitation, cannabigerol (CBG), cannabidivarin (CBDV), cannabichromene(CBC), cannabinol (CBN) and combinations thereof. Various strains ofhemp tend to present different ratios of these cannabinoids and, in duecourse, the desired ratios will also inevitably be geneticallyengineered, if not traditionally cross-bred. Whole, unextracted (nativeor activated) hemp that is fermented with fungal mycelium is thus ableto serve as a uniquely effective delivery system for any and allcannabinoids, including any additional beneficial hemp or cannabiscomponents now known or developed in the future.

The following example is illustrative.

EXAMPLE 1

As a test to illustrate the fiber ratios in native or activated hemp, aquantity of native hemp was subjected to a traditional extraction ofcannabinoids (not a part of the invention herein) by moderate crushingand extraction of cannabinoids to create a “hemp pomace” which continuedto include cannabinoids therein. The extraction was performed by carbondioxide solvent extraction. The resulting pomace was carefully air driedat 115 degrees Fahrenheit to prevent denaturing of all compounds andcompositions in the pomace. A representative dried pomace preparedaccording to the above method steps contained 6% moisture. Because onlyliquid was extracted from the native hemp, the fiber ratios of theresulting dried pomace were representative of the fiber ratios in thestarting native hemp (one form of hemp used in the fungal fermentationof the present invention). The fiber ratios of insoluble dietary fiber(IDF) to soluble dietary fiber (SDF) were 1:30 SDF/IDF.

Although the invention has been described with particularity above, theinvention is only to be limited insofar as is set forth in theaccompanying claims.

I claim:
 1. A method of co-fermenting one or more species of cannabiswith mycelial culture of one species of mushroom, comprising the stepsof: a) dividing any of aerial parts (leaves or flowers) of one or morecannabis species into particles having a major dimension of 1 cm orsmaller to create a quantity of shredded cannabis; b) admixing one partby weight of said shredded cannabis from step a) with at least one up totwo parts by weight of water to form a slurry; c) sterilizing saidslurry at at least 200 degrees F. for 2-4 hours and allowing the slurryto cool to 66-70 degrees F.; d) inoculating said slurry with solidmycelium culture; e) incubating an inoculated slurry formed in step d)at 66-70 degrees F. for 14-28 days to form a mycelial biomass; f) dryingsaid mycelial biomass at 110-165 degrees F. for 24-48 hours to create aco-fermentation product; and g) co-minuting said co-fermentation productto an aggregate of particulates.
 2. The method of claim 1, wherein saidcannabis is selected from the group consisting of: Cannabis indica,Cannabis sativa and Cannabis ruderalis.
 3. The method of claim 1,wherein said cannabis is hemp as defined by the 2018 Farm Bill.
 4. Themethod of claim 1, wherein said mushroom species is selected from thegroup consisting of: Ganoderma lucidum, Ganoderma japonicum, Ganodermaapplanatum, Ganoderma tsugae, Lentinula edodes, Grifola frondosus,Tremella fuciformia, Tremella mesenterica, Cordyceps sinensis, Cordycepsmilitaris, Hericium erinaceus, Polyporous umbellatus, Scizophylumcommune, Fomes fomentaris, Inonotuus obliquus, Lepiota procera,Auricularia auricula, Tuber melanosporum, Tricholoma matsutake, Hericiumcoralloides, Trametes versicolor, Phellinus linteus, Poria cocos,Antrodia camphorata, Flammulina velutipes, Pleurotus ostreatus,Pleurotus energyii, and Agaricus blazeii.
 5. The method of claim 1,wherein said particulates further comprise a powder.
 6. The method ofclaim 1, wherein the incubating step e) is conducted at 68 degrees F. 7.A co-fermentation product resulting from the method of claim
 1. 8. Theproduct according to claim 7, wherein said co-fermentation product has aSDF/IDF ratio of 1:25-29.
 9. The product according to claim 7, whereinsaid co-fermentation product contains compounds formed by mushroomculture metabolism of insoluble dietary fiber and other nutrients insaid cannabis.
 10. The product according to claim 7, wherein at no timeafter inoculating said slurry are said cannabis and said mushroomcomponents separated from said co-fermentation product.